Shang Yiyan, Wang Yunxia, Guo Yaxin, Li Shunian, Liao Jun, Hai Menglu, Wang Meiyun, Tan Hongna
Department of Radiology, People's Hospital of Henan University, Zhengzhou, Henan, People's Republic of China.
Department of Radiology, Henan Provincial People's Hospital, Zhengzhou, Henan, People's Republic of China.
Breast Cancer (Dove Med Press). 2024 Dec 14;16:957-972. doi: 10.2147/BCTT.S497770. eCollection 2024.
Core biopsy sampling may not fully capture tumor heterogeneity. Radiomics provides a non-invasive method to assess tumor characteristics, including both the core and surrounding tissue, with the potential to improve the accuracy of HER-2 status prediction.
To explore the clinical value of intratumoral and peritumoral radiomics features from dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) for preoperative prediction of human epidermal growth factor receptor-2 (HER-2) expression status in breast cancer.
Two tasks were designed, including Task1-distinguished HER-2 positive and HER-2 negative from 382 breast cancer patients and Task2-distinguished HER-2 low and HER-2 zero expression from 249 patients with HER-2 negative. Three radiomics models (intratumoral, peritumoral 5 mm, intratumoral+peritumoral 5 mm) were constructed based on decision tree, and clinical combined radiomics models were constructed with logistic regression based on clinicopathological features and radscore. The area under the curve (AUC), sensitivity, specificity, accuracy and decision curve analysis (DCA) were used to evaluate the predictive performance of models.
Estrogen receptor (ER), progesterone receptor (PR) and Ki67 showed statistically significant in the different groups of HER-2 expression. Additionally, magnetic resonance imaging-reported axillary lymph nodes (MRI-reported ALN) in the positive and negative groups and histological grade in the low and zero expression groups showed significant differences (all < 0.05). For task 1, the peritumoral radiomics model outperformed the other two radiomics models, with AUC values of 0.774 and 0.727 in the training and testing sets, respectively. For task 2, intratumoral + peritumoral radiomics model in the testing set showed the best predictive performance among the three radiomics models, and the AUC values were 0.777. The addition of clinicopathological features slightly altered the AUC values in both tasks.
Both radiomics methods based on DCE-MRI and the nomogram are helpful for preoperative prediction of HER-2 expression status.
核心活检取样可能无法完全捕捉肿瘤异质性。放射组学提供了一种非侵入性方法来评估肿瘤特征,包括核心组织和周围组织,有可能提高HER-2状态预测的准确性。
探讨动态对比增强磁共振成像(DCE-MRI)的瘤内和瘤周放射组学特征对乳腺癌术前预测人表皮生长因子受体2(HER-2)表达状态的临床价值。
设计了两项任务,包括任务1——从382例乳腺癌患者中区分HER-2阳性和HER-2阴性,以及任务2——从249例HER-2阴性患者中区分HER-2低表达和HER-2零表达。基于决策树构建了三种放射组学模型(瘤内、瘤周5mm、瘤内+瘤周5mm),并基于临床病理特征和radscore采用逻辑回归构建临床联合放射组学模型。采用曲线下面积(AUC)、敏感性、特异性、准确性和决策曲线分析(DCA)来评估模型的预测性能。
雌激素受体(ER)、孕激素受体(PR)和Ki67在HER-2表达的不同组中具有统计学意义。此外,阳性和阴性组的磁共振成像报告腋窝淋巴结(MRI报告的ALN)以及低表达和零表达组的组织学分级存在显著差异(均P<0.05)。对于任务1,瘤周放射组学模型优于其他两种放射组学模型,训练集和测试集的AUC值分别为0.774和0.727。对于任务2,测试集中的瘤内+瘤周放射组学模型在三种放射组学模型中显示出最佳预测性能,AUC值为0.777。临床病理特征的加入在两项任务中均略微改变了AUC值。
基于DCE-MRI的放射组学方法和列线图均有助于术前预测HER-2表达状态。